These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Grange C; Geninatti-Crich S; Esposito G; Alberti D; Tei L; Bussolati B; Aime S; Camussi G Cancer Res; 2010 Mar; 70(6):2180-90. PubMed ID: 20215497 [TBL] [Abstract][Full Text] [Related]
5. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice. Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000 [TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin. Fite BZ; Kheirolomoom A; Foiret JL; Seo JW; Mahakian LM; Ingham ES; Tam SM; Borowsky AD; Curry FE; Ferrara KW J Control Release; 2017 Jun; 256():203-213. PubMed ID: 28395970 [TBL] [Abstract][Full Text] [Related]
7. The release of Doxorubicin from liposomes monitored by MRI and triggered by a combination of US stimuli led to a complete tumor regression in a breast cancer mouse model. Rizzitelli S; Giustetto P; Faletto D; Delli Castelli D; Aime S; Terreno E J Control Release; 2016 May; 230():57-63. PubMed ID: 27049069 [TBL] [Abstract][Full Text] [Related]
11. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
12. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein. Wang T; Hartner WC; Gillespie JW; Praveen KP; Yang S; Mei LA; Petrenko VA; Torchilin VP Nanomedicine; 2014 Feb; 10(2):421-30. PubMed ID: 24028893 [TBL] [Abstract][Full Text] [Related]
13. Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics. Børresen B; Henriksen JR; Clergeaud G; Jørgensen JS; Melander F; Elema DR; Szebeni J; Engelholm SA; Kristensen AT; Kjær A; Andresen TL; Hansen AE ACS Nano; 2018 Nov; 12(11):11386-11398. PubMed ID: 30372038 [TBL] [Abstract][Full Text] [Related]
14. Peptidic Monodisperse PEG "Comb" as Multifunctional "Add-On" Module for Imaging-Traceable and Thermo-Responsive Theranostics. Zhu J; Zhang H; Chen K; Li Y; Yang Z; Chen S; Zheng X; Zhou X; Jiang ZX Adv Healthc Mater; 2020 Feb; 9(3):e1901331. PubMed ID: 31851435 [TBL] [Abstract][Full Text] [Related]
15. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474 [TBL] [Abstract][Full Text] [Related]
16. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo. Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618 [TBL] [Abstract][Full Text] [Related]
17. Porphyrin-phospholipid liposomes with tunable leakiness. Luo D; Carter KA; Razi A; Geng J; Shao S; Lin C; Ortega J; Lovell JF J Control Release; 2015 Dec; 220(Pt A):484-494. PubMed ID: 26578438 [TBL] [Abstract][Full Text] [Related]
18. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models. Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883 [TBL] [Abstract][Full Text] [Related]
19. Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors. Kuo PH; Teng YH; Cin AL; Han W; Huang PW; Wang LH; Chou YT; Yang JL; Tseng YL; Kao M; Chang MD Drug Deliv; 2020 Dec; 27(1):542-555. PubMed ID: 32241176 [TBL] [Abstract][Full Text] [Related]
20. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats. Hoving S; Seynhaeve AL; van Tiel ST; Eggermont AM; ten Hagen TL Anticancer Drugs; 2005 Jul; 16(6):667-74. PubMed ID: 15930896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]